Intraoperative search for the sentinal node using patent blue is considered a non risk procedure. We emphasize the highly exceptional nature of this adverse effect previously observed in other disciplines using this coloring agent. We present a case of allergic reaction to patent blue in a patient who underwent left mastectomy with sentinel lymph node. About 25 min after the dye injection, the patient developed increased heart frequency and allergic skin reaction. The patient was treated successfully with decreased inspired fraction of inhaled anesthetic and fluid replacement. The patient recovered uneventfully and was discharged from the PACU 3h after the end of surgery without skin changes and was discharged from hospital on the morning after surgery. Allergic reactions with the use of patent blue are far superior to the hypersensitivity reactions seen with anesthetic and adjuvant drugs. Therefore, the anesthesiologist must be aware of cardiovascular instability associated with skin changes during the use of patent blue, for early diagnosis and appropriate treatment of this hypersensitivity reaction to this dye. Skin tests done later confirmed allergy to patent blue dye; the tests induced a small syndrome reaction. Surgical personnel who use patent blue dye should be made aware of the risk of allergic reactions, sometimes severe, to this dye.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6430938PMC
http://dx.doi.org/10.11604/pamj.2018.31.7.15576DOI Listing

Publication Analysis

Top Keywords

patent blue
28
skin changes
8
allergic reactions
8
blue dye
8
patent
7
blue
7
dye
5
anaphylactic shock
4
shock patent
4
blue case
4

Similar Publications

Methemoglobinemia is a rare but potentially life-threatening condition in which hemoglobin is oxidized, impairing the oxygen-carrying capacity. While congenital forms exist, acquired methemoglobinemia can occur in perioperative settings, especially following exposure to oxidizing agents such as dyes used in sentinel lymph node biopsy (SLNB). Patent Blue V, a synthetic aniline dye commonly used for SLNB, has been associated with rare but serious adverse effects, including methemoglobinemia.

View Article and Find Full Text PDF

Background: The relationship between the extent and severity of stress-induced ischemia and the extent and severity of anatomic coronary artery disease (CAD) in patients with obstructive CAD is multifactorial and includes the intensity of stress achieved, type of testing used, presence and extent of prior infarction, collateral blood flow, plaque characteristics, microvascular disease, coronary vasomotor tone, and genetic factors. Among chronic coronary disease participants with site-determined moderate or severe ischemia, we investigated associations between ischemia severity on stress testing and the extent of CAD on coronary computed tomography angiography.

Methods: Clinically indicated stress testing included nuclear imaging, echocardiography, cardiac magnetic resonance imaging, or nonimaging exercise tolerance test.

View Article and Find Full Text PDF
Article Synopsis
  • Inadvertent intraneural injections during peripheral nerve blocks are common, and this study compares two detection methods: injection pressure monitoring and ultrasound imaging.
  • The research involved anesthesiologists conducting intraneural injections on fresh cadaver arms, measuring both pressure and sonographic images to evaluate outcomes.
  • Results showed that pressure monitoring detected intraneural injection much earlier than ultrasound (after just 0.2 mL vs. 1.2 mL for swelling), confirming that pressure monitoring is a more sensitive technique.
View Article and Find Full Text PDF

Background: Obesity is associated with excessive adipocyte-derived aldosterone secretion, independent of the classical renin-angiotensin-aldosterone cascade, and mineralocorticoid receptor antagonists may be more effective in patients with heart failure (HF) and obesity.

Objectives: This study sought to examine the effects of the nonsteroidal mineralocorticoid receptor antagonist finerenone compared with placebo, according to body mass index (BMI) in FINEARTS-HF (FINerenone trial to investigate Efficacy and sAfety superioR to placebo in paTientS with Heart Failure).

Methods: A total of 6,001 patients with HF with NYHA functional class II, III, and IV, a left ventricular ejection fraction of ≥40%, evidence of structural heart disease, and elevated natriuretic peptide levels were randomized to finerenone or placebo.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!